In a human-genetics sequencing study conducted with 58,335 participants, analysis showed that those who were heterozygous for ANGPTL3 loss-of-function variants had around 50% lower ANGPTL3 levels than noncarriers and a nearly 40% lower chance of coronary artery disease [37]. Here, ANGPTL3 is linked to coronary artery disorder.